FLASHDOSE
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

FLASHDOSE Trademark

Serial Number: 78543928

FLASHDOSE is a trademark filed by BIOVAIL LABORATORIES INTERNATIONAL SRL on January 7, 2005. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BIOVAIL LABORATORIES INTERNATIONAL SRL (42 trademarks)

WELCHES
CHRIST CHURCH BB17154 , BB

Entity Type: 99

BIOVAIL LABORATORIES INC (41 trademarks)

CHELSTON PARK
COLLYMORE, ST. MICHAELS WEST INDI , BB

Entity Type: 03

Trademark Details

Filing Date

January 7, 2005

Registration Date

Not Registered

Published for Opposition

May 2, 2006

Goods & Services

Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Oct 13, 2010 ASCK
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Aug 24, 2009 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Aug 24, 2009 ABN6
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jun 17, 2009 ASCK
SOU EXTENSION 5 GRANTED
Feb 5, 2009 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 5, 2009 AITU
SOU EXTENSION 5 FILED
Jan 22, 2009 EXT5
SOU TEAS EXTENSION RECEIVED
Jan 22, 2009 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 22, 2009 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 22, 2009 COAR
SOU EXTENSION 4 GRANTED
Jul 17, 2008 EX4G
SOU EXTENSION 4 FILED
Jul 17, 2008 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 17, 2008 EEXT
SOU EXTENSION 3 GRANTED
Feb 7, 2008 EX3G
SOU EXTENSION 3 FILED
Jan 18, 2008 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 18, 2008 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 29, 2007 TCCA
SOU EXTENSION 2 GRANTED
Sep 14, 2007 EX2G
SOU EXTENSION 2 FILED
Jul 12, 2007 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 12, 2007 EEXT
SOU EXTENSION 1 GRANTED
Dec 27, 2006 EX1G
SOU EXTENSION 1 FILED
Nov 9, 2006 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 9, 2006 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jul 25, 2006 NOAM
PUBLISHED FOR OPPOSITION
May 2, 2006 PUBO
NOTICE OF PUBLICATION
Apr 12, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 14, 2006 PREV
ASSIGNED TO LIE
Mar 10, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 8, 2006 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 3, 2006 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 9, 2006 TROA
NON-FINAL ACTION E-MAILED
Aug 9, 2005 GNRT
NON-FINAL ACTION WRITTEN
Aug 9, 2005 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2005 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 13, 2005 TCCA
NEW APPLICATION ENTERED
Jan 19, 2005 NWAP